english.prescrire.org > Spotlight > Archives : 2023 > Dutasteride, finasteride: high-grade prostate cancer (continued)

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

Dutasteride, finasteride: high-grade prostate cancer (continued)

 Adverse Effects  In the early 2010s, a trial of finasteride versus placebo in about 19 000 men with no clinical signs of prostate cancer found a decrease in the total number of diagnoses of prostate cancer in the finasteride group, but an increased incidence of particularly aggressive prostate cancer.
Full article (2 pages) available for download by subscribers

Finasteride and dutasteride are proposed as symptomatic treatment for benign prostatic hyperplasia. According to two double-­blind randomised placebo-­controlled trials and several epidemiological studies, they reduce the risk of any-­grade prostate cancer, but increase the risk of high-­grade prostate cancer.

©Prescrire 1 May 2023

Source: "Dutasteride, finasteride: high-grade prostate cancer (continued)" Prescrire International 2023; 32 (248): 132-133. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >